High intratumoral CD8
immunohistochemistry
prostate cancer
radical prostatectomy
tumor infiltrating lymphocyte
tumor tissue microarray
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
06
2020
accepted:
24
08
2020
pubmed:
22
10
2020
medline:
11
5
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
A high density of CD8 Tumor microarrays constructed from 230 patients with localized prostate cancers who underwent RP from 2006 to 2012 at Roswell Park Comprehensive Cancer Center were analyzed retrospectively using immunohistochemistry. CD8 One hundred and forty-nine (65%) patients had high risk diseases (Gleason >7 or pT3/4). The median follow-up time was 8.4 years. High CD8 Intratumoral CD8
Sections du résumé
BACKGROUND
A high density of CD8
METHODS
Tumor microarrays constructed from 230 patients with localized prostate cancers who underwent RP from 2006 to 2012 at Roswell Park Comprehensive Cancer Center were analyzed retrospectively using immunohistochemistry. CD8
RESULTS
One hundred and forty-nine (65%) patients had high risk diseases (Gleason >7 or pT3/4). The median follow-up time was 8.4 years. High CD8
CONCLUSION
Intratumoral CD8
Identifiants
pubmed: 33085799
doi: 10.1002/pros.24068
pmc: PMC9869431
mid: NIHMS1640858
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-28Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NIH HHS
ID : S10 OD019977
Pays : United States
Organisme : NIH HHS
ID : S10OD019977
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016056
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Urology. 1999 Nov;54(5):884-90
pubmed: 10565752
Cancer Immunol Res. 2016 Nov;4(11):948-958
pubmed: 27688020
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Eur Urol Focus. 2019 Mar;5(2):192-196
pubmed: 28753812
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Eur J Cancer. 2013 Apr;49(6):1273-9
pubmed: 23266046
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32269146
Mod Pathol. 2013 Mar;26(3):448-55
pubmed: 23041830
Clin Cancer Res. 2007 Dec 1;13(23):6947-58
pubmed: 18056169
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Cancer Cell. 2016 Mar 14;29(3):285-296
pubmed: 26977880
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
J Clin Pathol. 2007 Jun;60(6):694-700
pubmed: 16917000
Prostate. 2014 Oct;74(14):1452-61
pubmed: 25111810
Clin Cancer Res. 2011 Mar 15;17(6):1571-81
pubmed: 21159885
Clin Cancer Res. 2008 Jun 1;14(11):3254-61
pubmed: 18519750
J Immunol. 2006 Nov 15;177(10):7398-405
pubmed: 17082659
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
Clin Nucl Med. 2013 Jan;38(1):e26-32
pubmed: 23242060
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Pathol. 1997 Jul;182(3):318-24
pubmed: 9349235
Prostate. 2008 Jan 1;68(1):1-10
pubmed: 17948280
Int J Clin Exp Med. 2014 Apr 15;7(4):1175-9
pubmed: 24955204
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
BJU Int. 2012 Oct;110(8):1122-8
pubmed: 22373045
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70
pubmed: 11734652
Prostate. 2016 Sep;76(12):1095-105
pubmed: 27199259
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
J Immunol Methods. 2009 Aug 31;348(1-2):9-17
pubmed: 19552894
Urol Oncol. 2017 Dec;35(12):694-700
pubmed: 29146441
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
J Natl Cancer Inst. 2014 Sep 24;106(11):
pubmed: 25255802
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123